je.st
news
Tag: shire
Shire says FDA declines to approve eye drug Lifitegrast
2015-10-17 08:11:06| Biotech - Topix.net
The U.S. Food and Drug Administration notified Shire Plc it will not approve its eye drug Lifitegrast, the company said on Friday, adding that the U.S. health regulator recommended the company conduct additional clinical studies. The news comes over a week before the FDA was supposed to make a decision on Lifitegrast on Oct 25. Shire said it received a complete response letter, which the FDA sends to let a drug developer know a marketing application will not be approved in its present form.
The Wall Street Journal: Shire weighs options to sweeten all-stock offer for Baxalta
2015-09-14 09:09:43| Biotech - Topix.net
Shire PLC is weighing options for sweetening its multibillion-dollar, all-stock offer for U.S. biotechnology firm Baxalta Inc. by putting cash into shareholders' hands sooner, said people familiar with the matter. disclosed last month and valued at $30.6 billion based on Shire's stock price at the time-excluded any cash.
Tags: options
street
offer
journal
Undervalued Baxalta Shares Target of Acquisition by Shire Plc
2015-08-06 17:02:22| Biotech - Topix.net
Baxalta was recently spun-off from Baxter International on July 1st, 2015. The company has 16,000 employees and around $6 billion in expected revenues.
Tags: target
shares
acquisition
plc
Shire makes $30bn offer for Baxalta
2015-08-04 16:32:56| BBC News | Business | UK Edition
Shire, which makes the Adderall XR amphetamine, said it is seeking to buy fellow drugmaker Baxalta for $30bn (19.2bn).
Tags: offer
makes
shire
makes offer
Shire offers to buy Baxter drug spinoff for $30 billion
2015-08-04 15:21:34| Biotech - Topix.net
Irish drugmaker Shire PLC Is offering to buy Baxalta Inc. for about $30 billion in stock in a move to solidify its position in rare disease treatments. Deerfield, Illinois-based Baxalta was spun off of Baxter International Inc. in July and focuses on bleeding disorders.
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] next »